Professor of Ophthalmology and Visual Sciences, University of Illinois, Chicago
Vice Chairman and Director of Ocular Oncology
Thermo-responsive Hydrogels as a New Platform for Drug Delivery to the Posterior Segment of the Eye
Targeted, localized, extended drug delivery to the
posterior segment of the eye (retina) poses a number of significant
challenges. This presentation will review our work with
thermo-responsive hydrogel delivery of anti-VEGF agents to the retina.
Current treatment of age-related macular degeneration with anti-VEGF
agents involves an intravitreal injection of the medication every four
to six weeks. We are working toward a three to six month, non-invasive,
drug delivery system. This presentation will provide an overview of our
ongoing work.
Website >>
Dr.
Barrett Rabinow, PhD
Baxter Healthcare, Baxter Distinguished Scientist
Director of Strategic Development
Nanoparticles-Impact on PK and Distribution
The nanoparticles that will be discussed are crystalline drug particles, stabilized by surfactant coatings, prepared by a combination of precipitation followed by homogenization. Depending upon its dissolution rate, several pharmacokinetic scenarios can occur upon injection of a drug nanosuspension: 1) the suspension dissolves rapidly, affording pharmacokinetics equivalent to that for an a priori solution formulation,
2) the suspension releases slowly over time, permitting an SC, IM, or ID depot, sustained release dosage form, or 3) the particle suspension in blood does not dissolve quickly, but over a period of minutes traverses the pulmonary circulation, and is then taken up by the spleen and liver. This PK and distribution behavior is similar to that for intravenous injection of any inert particle suspension. This results in rapid uptake of the particles and slow subsequent release by the monocyte phagocytic system, to the extent that the drug can be solubilized within the macrophages. This can dramatically enhance efficacy for drugs whose toxicity is mediated by peak levels but whose efficacy is driven by AUC. Besides pharmacokinetic modification, targeting of nanosuspensions to sites of disease can be managed by harnessing the natural targeting capabilities of macrophages, which migrate to sites of inflammation, infection, and tumor. Case examples will be shown for anti-fungal enhancement of efficacy, anti-neoplastic agent improvement of PK, and targeting of the brain and other viral sanctuaries for treatment of HIV infection in animal models.Dr. Lonnie Shea, PhD
Associate Professor of Chemical and Biological Engineering, Northwestern
University
Biomaterials for delivery of gene therapy vectors in regenerative
medicine
Website >>
Dr. Joseph Wong, PhD
Baxter Healthcare, Principal Scientist
Product Development Considerations with Injectable Nanosuspensions
There has been growing interest in nanoparticles as an approach to
formulate poorly soluble drugs. Besides enhanced dissolution rates, and
thereby, improved bioavailability, nanoparticles can also provide
targeting capabilities when injected intravenously. The latter property
has led to increased research and development activities for intravenous
suspensions. Additional clinical trials have been conducted or are
ongoing for multiple other indications such as oncology and infective
diseases. This presentation provides an insight into various challenges
associated with developing intravenous nanosuspension dosage forms.
Website >>
Dr. Michael Kaminski, PhD
Argonne National Laboratory, Nuclear Forensics and Nanoscale Engineering
Chemical Engineering Division
Magnetic drug delivery technology
Primary obstacles to developing novel drugs are their poor
solubility, non-specific targeting, and cytotoxicity. Therefore,
adjuvants such as delivery vehicles can become important technologies to
improve drug discovery. One such delivery vehicle is magnetic carriers.
These are polymeric microspheres or nanospheres that co-encapsulate drug
and magnetic nanoparticles. The magnetic susceptibility allows the
carriers to be physically-positioned to improve targeting, enables
low-level detection by magnetic resonance, and allows drug release
profiles to be controlled. The polymeric substrate provides versatile
functionality to improve drug carrier circulation, attach specific
ligands for targeting, and protect the drug from inactivation by
blood-born enzymes. Dr. Kaminski will discuss the state-of-the-art in
magnetic drug carriers and activities that his laboratory has been
involved.
Website >>
04/26/2009 KAT contact kschwa4@uic.edu regarding this webpage
|
Start time |
End time |
Event |
Location |
|
8:00 |
8:30 |
Registration |
Floor |
|
8:30 |
8:40 |
Opening symposium remarks Vice Chancellor Larry Danziger, PharmD., Interim Vice Chancellor for Research at University of Illinois at Chicago
|
Chicago Rm A |
|
8:40 |
8:43 |
Opening symposium remarks Dean Jerry Bauman, PharmD., Dean of the University of Illinois at Chicago College of Pharmacy
|
Chicago Rm A |
|
8:43 |
8:45 |
Opening symposium remarks Misuk Bae, Chair, CRS -- Illinois Student Chapter
|
Chicago Rm A |
|
8:45 |
9:30 |
Keynote speaker: Dr. Theodore Roseman, former CRS President and VP at Baxter Title: Heparin: Unraveling the Mystery |
Chicago Rm A |
| 9:30 | 9:35 | Break | Floor |
|
9:35 |
10:20 |
Dr. Barrett Rabinow, Baxter Healthcare Title: Nanoparticles-Impact on PK and Distribution |
Chicago Rm A |
|
10:20 |
11:05 |
Dr. Joseph Wong, Baxter Healthcare Title: Product Development Considerations with Injectable Nanosuspensions |
Chicago Rm A |
|
11:05 |
1:00 |
Poster presentation & Luncheon/Round Table Discussion
|
Chicago Rm B |
|
1:15 |
2:00 |
Dr. William Mieler, University of Illinois at Chicago Title: Thermo-responsive Hydrogels as a New Platform for Drug Delivery to the Posterior Segment of the Eye |
Chicago Rm A |
|
2:00 |
2:45 |
Dr. Michael Kaminski, Argonne National Laboratory Title: Magnetic drug delivery technology |
Chicago Rm A |
| 2:45 | 2:50 | Break | Floor |
|
2:50 |
3:35 |
Dr. Lonnie Shea, Northwestern University Title: Biomaterials for delivery of gene therapy vectors in regenerative medicine |
Chicago Rm A |
| 3:35 | 3:50 | Presentation of Gift for Speakers, Poster Presentation Prize Awarded | Chicago Rm A |
|
3:50 |
3:55 |
Closing symposium remarks: Dr. Richard A. Gemeinhart, CRS -- Illinois Student Chapter Faculty Advisor
|
Chicago Rm A |
|
3:55 |
3:57 |
Closing symposium remarks: Misuk Bae, Chair, CRS -- Illinois Student Chapter
|
Chicago Rm A |